Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical hematoporphyrin photodynamic therapy plus BCG for recurrent non-muscle invasive bladder cancer after BCG
ChiCTR2100048195Phase 4Not yet recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hemoporfin and bcg vaccine in bladder cancer, sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-Free Survival. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
hemoporfinbcg vaccine
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2100048195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048195.